secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001493152-24-035960
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate starts final FDA-required study for lead ADHD asset CTx-1301; raises $10M+
--------------------------------------------------------------------------------

- Commenced final FDA-required food effect study for CTx-1301 (dexmethylphenidate) for ADHD; data readout expected by end of 2024.
- Raised over $10M in additional capital since mid-August 2024, including 58% from at-the-market facility.
- Received notification from Nasdaq that company is now in compliance with listing requirements.
- Reinstated CEO/COO/CFO base salaries to original levels ($503K, $424K, $350K) after late-2023 reductions.
- Cost containment measures have saved approximately $1.45M cumulatively; headcount remains ~40% below 2023 levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224035960/0001493152-24-035960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224035960/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-035960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer